Adverse Events Associated with High‐Dose Ribavirin: Evidence from the Toronto Outbreak of Severe Acute Respiratory Syndrome

Study Objectives. To distinguish adverse events related to ribavirin therapy from those attributable to severe acute respiratory syndrome (SARS), and to determine the rate of potential ribavirin‐related adverse events.

[1]  J. Leduc,et al.  Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. , 1991, The Journal of infectious diseases.

[2]  H. Kuo,et al.  Adverse Effects of Ribavirin and Outcome in Severe Acute Respiratory Syndrome , 2005, Chest.

[3]  Elizabeth J Phillips,et al.  Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  D. Altman,et al.  Multiple significance tests: the Bonferroni method , 1995, BMJ.

[5]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[6]  K. Yuen,et al.  Development of a standard treatment protocol for severe acute respiratory syndrome , 2003, The Lancet.

[7]  Y. Leo,et al.  Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003 , 2004, Tropical medicine & international health : TM & IH.

[8]  T. Gooley,et al.  Hypocalcemia: a pervasive metabolic abnormality in the critically ill. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  M. Loeb,et al.  Early diagnosis of SARS: lessons from the Toronto SARS outbreak , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[10]  C. Chu,et al.  SARS: prognosis, outcome and sequelae , 2003, Respirology.

[11]  B. Chernow,et al.  The multifactorial basis for hypocalcemia during sepsis. Studies of the parathyroid hormone-vitamin D axis. , 1987, Annals of internal medicine.

[12]  O. Tsang,et al.  Outcomes and Prognostic Factors in 267 Patients with Severe Acute Respiratory Syndrome in Hong Kong , 2003, Annals of Internal Medicine.

[13]  J H Ellenberg,et al.  Selection bias in observational and experimental studies. , 1994, Statistics in medicine.

[14]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[15]  C. Cameron,et al.  The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase , 2001, Current opinion in infectious diseases.

[16]  L. Gluud,et al.  Ribavirin Monotherapy for Chronic Hepatitis C Infection: A Cochrane Hepato-Biliary Group Systematic Review and Meta-Analysis of Randomized Trials , 2006, The American Journal of Gastroenterology.

[17]  P. Hawkey,et al.  Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. , 2003, Journal of medical microbiology.

[18]  Gideon Koren,et al.  Ribavirin in the treatment of SARS: A new trick for an old drug? , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[19]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[20]  H. Doerr,et al.  Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus , 2003, The Lancet.

[21]  Chong-Jen Yu,et al.  Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS Patients , 2004, Emerging infectious diseases.

[22]  Y. Guan,et al.  Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.

[23]  Hsin-Pai Chen,et al.  Clinical Characteristics, Management and Prognostic Factors in Patients with Probable Severe Acute Respiratory Syndrome (SARS) in a SARS Center in Taiwan , 2005, Journal of the Chinese Medical Association.

[24]  T. Ksiazek,et al.  Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  G. McEvoy,et al.  AHFS Drug Information , 1994 .

[26]  Arthur S Slutsky,et al.  Identification of severe acute respiratory syndrome in Canada. , 2003, The New England journal of medicine.

[27]  Philip K. Russell,et al.  Hemorrhagic fever viruses as biological weapons: medical and public health management. , 2002, JAMA.

[28]  J. Schafer.  Multiple imputation: a primer , 1999, Statistical methods in medical research.

[29]  Ching-lung Lai,et al.  SARS‐associated viral hepatitis caused by a novel coronavirus: Report of three cases , 2004, Hepatology.

[30]  M. Lai,et al.  Meta‐analysis: ribavirin‐induced haemolytic anaemia in patients with chronic hepatitis C , 2002, Alimentary pharmacology & therapeutics.

[31]  S. Lai,et al.  Value of initial chest radiographs for predicting clinical outcomes in patients with severe acute respiratory syndrome , 2004, The American Journal of Medicine.

[32]  Z. Zou,et al.  Prognostic Factors for Severe Acute Respiratory Syndrome: A Clinical Analysis of 165 Cases , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  N. Zhong,et al.  SARS: pharmacotherapy , 2003, Respirology.

[34]  J. McCormick,et al.  Lassa fever. Effective therapy with ribavirin. , 1986, The New England journal of medicine.

[35]  T. Wright,et al.  The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients , 2003, Journal of viral hepatitis.

[36]  J. Huggins.  Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. , 1989, Reviews of infectious diseases.

[37]  R. Holman,et al.  Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience , 1998, Antiviral therapy.

[38]  F. Aoki,et al.  Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α , 2004, The Journal of infectious diseases.

[39]  Y. Guan,et al.  In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds , 2004, Journal of Clinical Virology.

[40]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[41]  M. Avendaño,et al.  Clinical course and management of SARS in health care workers in Toronto: a case series. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[42]  R. K. Robins,et al.  Broad-Spectrum Antiviral Activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamide , 1972, Science.

[43]  M. Loeb,et al.  Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. , 2004, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[44]  S. Ng,et al.  Severe acute respiratory syndrome: prognostic implications of chest radiographic findings in 52 patients. , 2004, Radiology.

[45]  C. Broome,et al.  Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection , 1993, Pediatrics.

[46]  Elizabeth Rea,et al.  Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. , 2003, JAMA.

[47]  N. Schluger,et al.  Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  Elizabeth Rea,et al.  Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto. , 2004, The New England journal of medicine.

[49]  J. Maiztegui,et al.  Antiviral treatment of Argentine hemorrhagic fever. , 1994, Antiviral research.